AstraZeneca may expose coronavirus vaccine participants to pathogen

The chief executive of AstraZeneca, which is developing a leading coronavirus vaccine with Oxford University, said it is too early to deliberately expose trial participants to the pathogen, but it may become an option if ongoing tests hit a snag. The British drugmaker last week started phase 2 and 3 trials of the vaccine, looking… Continue reading at New York Post